Estee Lauder (EL) Misses Q4 EPS by 34c, Offers Q1 Outlook
Get Alerts EL Hot Sheet
Price: $84.53 --0%
EPS Growth %: +255.6%
Financial Fact:
Operating Income: 418M
Today's EPS Names:
MAYS, CRMT, REPL, More
EPS Growth %: +255.6%
Financial Fact:
Operating Income: 418M
Today's EPS Names:
MAYS, CRMT, REPL, More
Join SI Premium – FREE
Estee Lauder (NYSE: EL) reported Q4 EPS of ($0.53), $0.34 worse than the analyst estimate of ($0.19). Revenue for the quarter came in at $2.43 billion versus the consensus estimate of $2.45 billion.
GUIDANCE:
Estee Lauder sees Q1 2021 EPS of $0.80-$0.85, versus the consensus of $1.22.
Sales Outlook
- Reported net sales are forecasted to decline between 12% and 13% versus the prior-year period.
- The Company’s recent acquisition of Dr. Jart+ is forecasted to contribute approximately 2.5% to the Company’s overall sales growth.
- Excluding the impact of the acquisition and 1% negative impact from currency, net sales are forecasted to decrease between 14% and 15%.
Earnings per Share Outlook
- Reported diluted net earnings per common share are projected to be between $.77 and $.83. Excluding restructuring and other charges and adjustments, diluted net earnings per common share are projected to be between $.80 and $.85.
- Excluding the $.06 per share dilution related to the acquisition, adjusted diluted earnings per common share are expected to decrease between 45% and 48% on a constant currency basis.
- Currency exchange rates are volatile and difficult to predict. Using June 30, 2020 spot rates for fiscal 2021, the negative currency impact equates to about $.01 of diluted loss per share.
- The Company expects to take charges associated with previously approved restructuring and other activities. For Leading Beauty Forward, the charges are estimated to be between approximately $10 million to $15 million, equal to $.02 to $.03 per diluted common share. The first quarter fiscal 2021 forecast does not include charges related to the Post-COVID Business Acceleration Program
For earnings history and earnings-related data on Estee Lauder (EL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BofA lists top 5 themes driving next $1tn in incremental semi sales
- Amylyx ALS drug shows no serious adverse events in Phase 1 trial
- Rio2 Updates Condestable Mine Resources & Reserves
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Definitive AgreementSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share